Related Experiment Video
Updated: Mar 30, 2026
04:38
Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
Published on: March 28, 2018
16.8K
Proposed therapies in primary biliary cholangitis
Annarosa Floreani1, Ying Sun2,3, Zheng Sheng Zou3
1Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy.
Expert Review of Gastroenterology & Hepatology
|November 19, 2015
Summary
Primary biliary cholangitis (PBC) is an autoimmune liver disease. While ursodeoxycholic acid (UDCA) is a standard treatment, many patients need novel therapies targeting immune responses and cholestasis.
Area of Science:
- Hepatology
- Immunology
- Autoimmune Diseases
Background:
- Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease.
- It is characterized by anti-mitochondrial antibodies and often treated with ursodeoxycholic acid (UDCA).
- A significant portion of patients (20-40%) show an incomplete response to UDCA, facing increased disease progression risk.
Purpose of the Study:
- To review current clinical trials for primary biliary cholangitis.
- To discuss the rationale behind selecting therapeutic agents targeting aberrant immune responses in PBC.
- To explore emerging treatments aimed at ameliorating cholestasis.
Main Methods:
- Review of ongoing clinical trials in primary biliary cholangitis.
- Analysis of immunobiology and therapeutic targets in PBC.
- Discussion of novel agents for immune modulation and cholestasis management.
Main Results:
- Significant advances in understanding PBC immunobiology have not yet led to widespread new therapies.
- Current treatments include broad immunosuppression (corticosteroids) and targeted immunotherapies (T and B cell therapies).
- Emerging therapies like obeticholic acid focus on ameliorating cholestasis.
Conclusions:
- There is a critical need for novel therapeutic strategies for PBC patients unresponsive to UDCA.
- Future treatments will likely involve a combination of immunomodulatory and cholestasis-ameliorating agents.
- Ongoing clinical trials are exploring diverse approaches to effectively manage aberrant immune responses in PBC.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
479
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
479
01:29Inflammatory Bowel Disease IV: Pharmacological Management
935
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
935
01:17Chronic Bowel Disorders: Introduction
910
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
910
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
741
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
741
01:30Acute Pancreatitis II: Clinical Manifestations and Management
1.1K
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
1.1K
01:26Peptic Ulcer Disease IV: Management
635
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
635